



October 5, 2018

FunPep Co., Ltd.

Announcement of Fund Raising through Third Party Allocation of New Shares

FunPep Co., Ltd. ("FunPep") is pleased to announce that it has raised a total of approximately 460 million yen through a third-party allocation of new shares to business partners and venture capitalists.

Based on joint research with the Osaka University Graduate School of Medicine and other institutions, FunPep is engaged in the research and development of antibody-inducing peptides as therapeutic vaccines for various diseases and functional peptides as raw materials for cosmetics.

With the funds raised at this time, we will advance and expand our R&D pipeline for functional peptides, including antibody-inducing peptides, and strive to further enhance our corporate value.

【Subscribers】 (Alphabetical Order)

<Corporations>

- Sumitomo Dainippon Pharma Co.
- Fancl Co.
- Medipal Holdings Corporation
- Morishita Jintan Co.
- Shionogi & Co.

<Venture Capital>

- Bio-Site Capital Inc.
- Bio-Site Start Investment Limited Partnership (Operator: Bio-Site Capital Inc.)
- Mizuho Growth Support Investment Limited Liability Partnership (Operator: Mizuho Capital Co., Ltd.)